Case Report

Ischemic Retinal Vasculitis Associated with Cataract Surgery and Intracameral Vancomycin

Lucas T. Lenci, 1 Eric K. Chin, 1 Christi Carter, 1 Stephen R. Russell, 1 and David R. P. Almeida 2

1Department of Ophthalmology & Visual Sciences, University of Iowa Hospitals & Clinics, Iowa City, IA 52240, USA
2Vitreoretinal Surgery, PA, 7760 France Avenue S., Minneapolis, MN 55435, USA

Correspondence should be addressed to Lucas T. Lenci; lucas-lenci@uiowa.edu

Received 6 August 2015; Revised 6 October 2015; Accepted 12 October 2015

Academic Editor: Cristiano Giusti

Copyright © 2015 Lucas T. Lenci et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Recently, there have been reports suggesting that intracameral vancomycin has been associated with retinal vasculitis; some have described this phenomenon as postoperative hemorrhagic occlusive retinal vasculitis. We present a case of a 65-year-old woman who underwent uncomplicated phacoemulsification and posterior chamber intraocular lens implantation followed by intracameral antibiotic prophylaxis. Unlike prior reports, this report demonstrates a case of mild visual reduction and minimal inflammation with subtle but complete unilateral peripheral retinal ischemia associated with cataract surgery and intracameral vancomycin, suggesting a spectrum of toxicity that may be underrecognized.

1. Introduction

Cataract surgery may be associated with postoperative inflammatory or infectious complications, such as toxic anterior segment syndrome (TASS) or endophthalmitis. Typically, TASS or endophthalmitis is heralded by a disproportionate reduction in vision or increase in inflammation. Prior cases reported to be retinal vasculitis associated with cataract surgery and intracameral vancomycin injection showed similar reduction in vision with marked inflammation [1, 2]. In this report, we present a case of mild visual reduction and minimal inflammation with subtle but complete unilateral peripheral retinal ischemia associated with cataract surgery and intracameral vancomycin, suggesting a spectrum of toxicity that may be underrecognized.

2. Case Report

A 65-year-old woman with a past medical history of hypertension underwent uncomplicated phacoemulsification cataract extraction with implantation of a posterior chamber intraocular lens (PCIOl) in her right eye (OD) that concluded with injection of intracameral vancomycin (Hospira, NDC# 00409-4332-01, Lot# 396158E02, expiration 3/1/2016, concentration 1.0 mg/0.1 cc) as routine infection prophylaxis. Ofloxacin and prednisolone acetate 1% were postoperatively prescribed. On postoperative day 1, her vision was 20/20; however, this decreased two days later to 20/400. There was a 0.9–1.2 log unit relative afferent papillary defect (RAPD) OD. Intraocular pressure (IOP) was 18 mmHg OD. Slit-lamp examination of the right eye revealed mild conjunctival injection, trace corneal edema, deep anterior chamber with trace cell and flare but no hypopyon or fibrin, and a PCIOl in the capsular bag with no pigment or inflammatory deposits on the lens. The vitreous was quiet with no cells. On dilated examination, the optic nerve was normal with no disc edema or disc hemorrhage and a cup-to-disc ratio of 0.3. The retinal vessels were attenuated with box-carring and areas of arteriolar nonperfusion with distal branch retinal artery occlusions and scattered dot-blot hemorrhages in the periphery (Figure 1(a)). The left eye was normal with no abnormal findings except moderate nuclear sclerosis. The
Figure 1: Presentation of ischemic hemorrhagic retinal vasculitis after cataract surgery with intracameral vancomycin. Color fundus montage photograph displays attenuated retinal vessels with arteriolar nonperfusion and distal branch retinal artery occlusions (a). Goldmann visual field shows enlargement of the blind spot to the I4e isopter, paracentral scotoma to the I4e isopter, and central constriction of the I1e and I2e isopters (b). Optical coherence tomography illustrates adequate representation of all retinal layers (c). Fluorescein angiography with delayed retinal and choroidal filling in the mid frame (d). Late frames show numerous peripheral branch retinal artery occlusions (e) and scattered areas of vessel wall hyperfluorescence (f). The left eye was normal with no abnormal findings except moderate nuclear sclerosis.

3. Discussion

We present a case of ischemic retinal vasculitis associated with intraoperative intracameral vancomycin during cataract surgery. In the literature, there is one report of two cases of retinal vasculitis after cataract surgery with vancomycin and one more recent case series which described this sequela as postoperative hemorrhagic occlusive retinal vasculitis [1, 2]. In contrast to the prior reported cases that had severe anterior chamber and vitreous inflammatory reactions with profound irreversible vision loss, our case had minimal inflammatory reaction and significant retinal vasculitis with multiple arterial occlusions in a circular distribution about the posterior pole. The present case demonstrated rapid resolution when treated with a short course of topical medications.
Figure 2: Resolution of ischemic retinal vasculitis after eight weeks. Color fundus montage photograph shows posterior pole arteriolar sheathing with attenuation in the retinal periphery (a). Goldmann visual field shows resolution of previous visual field defects (b). Optical coherence tomography is stable compared to previous with adequate representation of all retinal layers (c). The left eye was never affected.

Although it is impossible to confirm the relationship of this disease to vancomycin exposure, we believe that it is unlikely to be related to an underlying systemic process or autoimmune disease. The patient had no history of hypertensive episodes or history of thrombosis. This contention is also supported by the abrupt onset, rapid resolution, temporal and ipsilateral association to vancomycin and the lack of prior symptoms or signs of uveitis, and negative laboratory workup. Although we believe the etiology is unlikely to be TASS (there were no other affected cases at the same surgery center on that day and our case had minimal anterior chamber reaction), the most provocative finding was the rapid normalization of the afferent pupillary defect and vision.

Vancomycin has been recommended for widespread prophylactic use in cataract surgery [3, 4]. Vancomycin is also widely used as an intravitreal injection for endophthalmitis [5]. Vancomycin retinal toxicity has been demonstrated in rabbits receiving intravitreal injections of vancomycin in silicone-filled eyes but human toxicity has not been suggested until recently [1, 6]. If this case represents the mild end of a spectrum of vancomycin toxicity, we believe that prospective evaluation will be needed to determine the incidence of the transitory and variable nature of the visual impact of widespread vancomycin surgical prophylaxis.

**Conflict of Interests**

The authors have no financial or conflict of interests to disclose.

**Authors’ Contribution**

David R. P. Almeida had full access to all the data in the study and takes full responsibility for the integrity of the data and the accuracy of the data analysis. All authors were responsible for design and conduct of the study. Collection, management, analysis, and interpretation of the data were the responsibility of all authors. Preparation, review, and approval of the paper were done by all authors. Decision to submit the paper for publication was made by all authors.

**References**

[1] L. B. Nicholson, B. T. Kim, J. Jardón et al., “Severe bilateral ischemic retinal vasculitis following cataract surgery,” *Ophthalmic Surgery, Lasers and Imaging Retina*, vol. 45, no. 4, pp. 338–342, 2014.

[2] A. J. Witkin, A. R. Shah, R. E. Engstrom et al., “Postoperative hemorrhagic occlusive retinal vasculitis: expanding the clinical spectrum and possible association with vancomycin,” *Ophthalmology*, vol. 122, no. 7, pp. 1438–1451, 2015.

[3] D. R. Anijeeet, P. Palimar, and C. O. Pecker, “Intracameral vancomycin following cataract surgery: an eleven-year study,” *Clinical Ophthalmology*, vol. 4, no. 1, pp. 321–326, 2010.

**Ethical Approval**

The authors fully adhered to the Declaration of Helsinki and all Federal and State laws.
[4] D. M. Gore, R. I. Angunawela, and B. C. Little, “United Kingdom survey of antibiotic prophylaxis practice after publication of the ESCRs Endophthalmitis Study,” Journal of Cataract and Refractive Surgery, vol. 35, no. 4, pp. 770–773, 2009.

[5] C. A. Lemley and D. P. Han, “Endophthalmitis: a review of current evaluation and management,” Retina, vol. 27, no. 6, pp. 662–680, 2007.

[6] H. M. Hegazy, M. Kivilcim, G. A. Peyman et al., “Evaluation of toxicity of intravitreal ceftazidime, vancomycin, and ganciclovir in a silicone oil-filled eye,” Retina, vol. 19, no. 6, pp. 553–557, 1999.